Breaking News
Freenome
About Freenome
Freenome is on a mission to empower everyone with the tools they need to detect, treat, and ultimately prevent cancer.
We have pioneered the most comprehensive multiomics platform for early cancer detection through a routine blood draw. By combining deep expertise in molecular biology with advanced computational biology and machine learning techniques to recognize disease-associated patterns among billions of circulating, cell-free biomarkers, we are developing simple and accurate blood tests for early cancer detection and integrating the actionable insights into health systems to operationalize a machine learning feedback loop between care and science.
Our recent $270 Million Series C brings our financing to over $500 million from investors, including; Bain Capital, Perceptive Advisors, RA Capital, Polaris Partners, Andreessen Horowitz, funds and accounts advised by T. Rowe Price Associates, Inc., GV (formerly Google Ventures), Roche Venture Fund, Kaiser Permanente Ventures, American Cancer Society’s BrightEdge Ventures, Data Collective Venture Capital, Novartis and Verily Life Sciences.
Freenome Launches Its First Study for the Detection of Multiple Cancers That Pairs Multiomics With Real-World Data
September 8 2022
Freenome, a privately held biotech company, today announced the launch of the Sanderson Study, the […]
Largest Clinical Study Validating A Blood-based Colorectal Screening Test Completes Enrollment
May 11 2022
Freenome, a privately held biotech company, announced the completion of enrollment for PREEMPT CRC, the […]
Lance Baldo Joins Freenome as Chief Medical Officer
April 5 2022
Freenome, a privately held biotech company, announced today that Lance Baldo, M.D. has joined the […]
Freenome Launches The Vallania Study For The Early Detection Of Multiple Cancers
March 1 2022
Freenome, a privately held biotech company, today announced the initiation of Vallania, a clinical study […]
Freenome Presents Research Highlighting its Multiomics Blood Testing Platform in PREEMPT CRC
January 24 2022
Freenome, a privately held biotech company, presented at the American Society of Clinical Oncology Gastrointestinal […]
Significant Investment Accelerates Freenome's Multiomics Platform for the Early Detection of Cancer
January 12 2022
Freenome, a privately held biotech company, announced today that Roche has made an investment of $290 […]
Freenome Raises $300M in Series D Financing to Advance Multiomics Platform for Early Cancer Detection
December 8 2021
Freenome, a privately held biotech company, today announced a Series D funding of $300 million. […]
Freenome Shows Continued Leadership in Colorectal Cancer Research
October 26 2021
Freenome, a privately held biotech company, presented new research at the American College of Gastroenterology […]
New Study Finds Freenome ’s Multiomics Approach Successful in Detecting Pancreatic Cancer
October 1 2021
Freenome, a privately-held biotech company, presented new research today at the American Association of Cancer […]